NCT04969861View on ClinicalTrials.gov

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

April 22, 2022

Study Completion Date

April 22, 2022

Conditions
Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
Interventions
DRUG

Bempegaldesleukin

Specified dose on specified days

DRUG

Pembrolizumab

Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Trial Locations (4)

5020

Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg

68114

Nebraska Methodist Hospital, Omaha

Unknown

Attikon University General Hospital, Athens

ASST Degli Spedali Civili di Brescia, Brescia

Sponsors
All Listed Sponsors
collaborator

SFJ Pharmaceuticals, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Nektar Therapeutics

INDUSTRY

NCT04969861 - BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Biotech Hunter | Biotech Hunter